Accute and repeated DSS exposure induce distinct immune responses with differential relevance to human Ulcerative Colitis
Download from source ↗Dataset overview
Repeated Dextran Sulfate Sodium Exposure Elicits Distinct Immune Responses Reflecting Human Ulcerative Colitis.
Abstract
<h4>Background & aims</h4>Dextran sulfate sodium (DSS)-induced colitis is a widely used model to study ulcerative colitis (UC). However, the extent to which acute vs repeated DSS exposure mimics human disease remains unclear.<h4>Methods</h4>Using histopathology, flow cytometry, single-cell RNA sequencing (scRNA-seq), and 16S rRNA profiling, we compared disease outcomes, immune infiltrate, transcriptional programs, and changes in the microbiome in mice subjected to a single (acute) vs 2 (repeated) DSS cycles. We further evaluated which experimental condition better represents key immune cell subtype states in human disease.<h4>Results</h4>Although disease activity indices were similar between groups, repeated DSS exposure resulted in greater colon shortening, mucosal remodeling, and elevated immune infiltration, particularly by neutrophils (PMNs) in the distal colon. scRNA-seq revealed that PMNs and T cells acquired distinct transcriptional programs in repeated vs acute colitis. Cycle 1 PMNs showed inflammatory and cytotoxic signatures, whereas cycle 2 PMNs were enriched in tissue remodeling and survival pathways. CD4 and CD8 T cells in repeated colitis exhibited migratory, and pathogen-responsive phenotypes, with expanded regulatory T cells and exhausted CD8 subsets. In contrast, macrophage numbers decreased with repeated DSS, though remaining cells exhibited pro-resolution gene expression profiles. Microbiome analysis revealed normalization trends with repeated DSS exposure, including reduced proinflammatory and increased beneficial genera. Cross-species transcriptomic comparisons indicated cycle-specific overlap with human UC, where cycle 2 activated PMNs and alternatively activated macrophages, closer aligned with active human UC.<h4>Conclusions</h4>Collectively, our data indicate that repeated DSS cycles provide a better experimental colitis model for studying immune cells in UC and identifying distinct immune subtypes relevant to UC therapeutics.
doi:10.1016/j.jcmgh.2025.101714 ↗ PMID 41453640 ↗ PMC12892045 ↗
Study facts
- Organism
- Homo sapiens; Mus musculus
- Platform
- Illumina NovaSeq X Plus
- Age group
- —
- Disease groups
- —
- Anatomical sites
- colon
Data availability
- Raw counts
- Processed matrix
File types
MTXTSV
Files and samples
- filelist.txt ↗
- GSE306845_RAW.tar ↗
- GSM9210595_B_Inactive_UC_barcodes.tsv.gz ↗
- GSM9210595_B_Inactive_UC_features.tsv.gz ↗
- GSM9210595_B_Inactive_UC_matrix.mtx.gz ↗
- GSM9210596_C_Inactive_UC_barcodes.tsv.gz ↗
- GSM9210596_C_Inactive_UC_features.tsv.gz ↗
- GSM9210596_C_Inactive_UC_matrix.mtx.gz ↗
- GSM9210597_D_Inactive_UC_barcodes.tsv.gz ↗
- GSM9210597_D_Inactive_UC_features.tsv.gz ↗
- GSM9210597_D_Inactive_UC_matrix.mtx.gz ↗
- GSM9210598_E_Inactive_UC_barcodes.tsv.gz ↗
- GSM9210598_E_Inactive_UC_features.tsv.gz ↗
- GSM9210598_E_Inactive_UC_matrix.mtx.gz ↗
- GSM9210599_F_Inactive_UC_barcodes.tsv.gz ↗
- GSM9210599_F_Inactive_UC_features.tsv.gz ↗
- GSM9210599_F_Inactive_UC_matrix.mtx.gz ↗
- GSM9210600_G_Inactive_UC_barcodes.tsv.gz ↗
- GSM9210600_G_Inactive_UC_features.tsv.gz ↗
- GSM9210600_G_Inactive_UC_matrix.mtx.gz ↗
- GSM9210601_WT_cycle1_N1_barcodes.tsv.gz ↗
- GSM9210601_WT_cycle1_N1_features.tsv.gz ↗
- GSM9210601_WT_cycle1_N1_matrix.mtx.gz ↗
- GSM9210602_WT_cycle1_N2_barcodes.tsv.gz ↗
- GSM9210602_WT_cycle1_N2_features.tsv.gz ↗
- GSM9210602_WT_cycle1_N2_matrix.mtx.gz ↗
- GSM9210603_WT_cycle2_N1_barcodes.tsv.gz ↗
- GSM9210603_WT_cycle2_N1_features.tsv.gz ↗
- GSM9210603_WT_cycle2_N1_matrix.mtx.gz ↗
- GSM9210604_WT_cycle2_N2_barcodes.tsv.gz ↗
- GSM9210604_WT_cycle2_N2_features.tsv.gz ↗
- GSM9210604_WT_cycle2_N2_matrix.mtx.gz ↗
- index.html ↗
- colon biopsy6
- Colon tissue4
| Accession | Sample | Tissue | Molecule |
|---|---|---|---|
GSM9210595 |
Colon biopsy from Inactive UC patient, sample B | colon biopsy | total RNA |
GSM9210596 |
Colon biopsy from Inactive UC patient, sample C | colon biopsy | total RNA |
GSM9210597 |
Colon biopsy from Inactive UC patient, sample D | colon biopsy | total RNA |
GSM9210598 |
Colon biopsy from Inactive UC patient, sample E | colon biopsy | total RNA |
GSM9210599 |
Colon biopsy from Inactive UC patient, sample F | colon biopsy | total RNA |
GSM9210600 |
Colon biopsy from Inactive UC patient, sample G | colon biopsy | total RNA |
GSM9210601 |
Colon digest of cycle 1 (2.5%) DSS, sample 1 | Colon tissue | total RNA |
GSM9210602 |
Colon digest of cycle 1(2.5%)DSS, sample 2 | Colon tissue | total RNA |
GSM9210603 |
Colon digest of cycle 2 (2.5%) DSS, sample 1 | Colon tissue | total RNA |
GSM9210604 |
Colon digest of cycle 2 (2.5%) DSS, sample 2 | Colon tissue | total RNA |
Strengths & limitations for reuse
Strengths
- Raw reads are advertised
- Raw counts are advertised
- Processed matrices are advertised
- Cell metadata are advertised
- Participant counts are documented
Extraction evidence & provenance
Each extracted field is shown with the source excerpt and location used to resolve it.
Assay
| Field | Value | Evidence |
|---|---|---|
assay.assay_type |
RNA-Seq |
Expression profiling by high throughput sequencing Section |
assay.library_chemistry |
10x Genomics Single Cell 3′ Reagents kit v3 |
Libraries for both human and mouse samples were generated using Genomics Single Cell 3′ Reagents kit (v3) Section |
assay.platform |
Illumina NovaSeq X Plus |
Illumina NovaSeq X Plus Section |
assay.reference_genome |
GRCh38; GRCm38 |
aligned to either Mus musculus reference genome (GRCm38) or human GRCh38 Section |
assay.sequencing_type |
scrna_seq |
we performed a single-cell mRNA sequencing (scRNA-seq) Section |
Cohort
| Field | Value | Evidence |
|---|---|---|
cohort.disease_activity_metadata_available |
True |
Human colonic biopsies were obtained from consented inactive UC patients (Mayo endoscopic scores of 0) Section |
cohort.total_participants |
6 |
integrating 4 patients with active disease and 6 patients in remission Section |
cohort.treatment_exposure_documented |
True from source |
GEO sample characteristics document treatment/therapy Section |
cohort.ulcerative_colitis_participants |
6 |
"Inactive UC": 6 Section |
Data_Assets
| Field | Value | Evidence |
|---|---|---|
data_assets.cell_metadata |
True |
tab-delimited text file includes cell and gene unique identifiers Section |
data_assets.open_access |
True |
Public on Oct 31 2025 Section |
data_assets.processed_matrix |
True |
Supplementary files format and content: mtx file contains counts for each sample Section |
data_assets.raw_counts |
True |
Supplementary files format and content: mtx file contains counts for each sample Section |
data_assets.raw_reads |
True |
GSE306845_RAW.tar Section |
Processing
| Field | Value | Evidence |
|---|---|---|
processing.batch_correction_reported |
True |
integration using harmony Section |
processing.cell_type_annotation_method |
differentially expressed genes and common lineage markers |
annotated into cell types based on differentially expressed genes (DEGs) and common lineage markers Section |
processing.normalization_method |
sctransform |
Data was normalized and scaled using sctransform Section |
processing.quality_control_reported |
True |
Each sample was filtered using a dynamic per-sample upper limit for gene count, UMI count, and percent ribosomal genes Section |
Specimens
| Field | Value | Evidence |
|---|---|---|
specimens.anatomical_sites |
['colon'] |
RNA seq profiling of colonic biopsies of inactive UC patients and colon digest of C57/BL/6J mice Section |
specimens.inflamed_status_available |
True |
"treatment": "Inactive UC" Section |
specimens.number_of_cells |
79238 inferred |
After filtering, 51,464 (55%) of human and 27,774 (78%) of mouse cells remained Section |
specimens.number_of_samples |
10 |
"sample_count": 10 Section |
specimens.specimen_type |
mixed |
RNA seq profiling of colonic biopsies of inactive UC patients and colon digest of C57/BL/6J mice during 1 cycle and 2 cycles (2.5%) DSS. Section |